Kurma Partners

We have built a strong network of partners with the best European academic research players, to transform their disruptive scientific discoveries into cutting-edge medicines or medical devices to diagnose and treat patients with severe diseases with high unmet medical need

Our ambition is to work with leading European research centers to build the healthcare industry of tomorrow In that perspective, we have developed a unique approach We work closely with the research teams early on to define a plan to validate their discoveries and bring together the best healthcare industry experts and later the most experienced entrepreneurs to create high-tech companies We provide capital/funding to the companies we have founded with our funds and invite other investors to join us This new and distinctive approach makes us stand out from most players in the world of healthcare investment and has enabled us to build more than 10 companies over the past 10 years We are also involved in early stage companies that have already been created, but always by supporting their development by providing our expertise and network We have thus contributed to the financing of more than 40 companies, many of which have become recognized leaders in their respective sectors

Because of our business, we are players in the world of healthcare and as such are committed to making our contribution to sustainable development We adhere to the ESG practices we have established 2018 First closing of Kurma Biofund III 2019 Opening of the office in Germany

• The raison d’être of Kurma Partners fits perfectly with a proactive impact and ethical policy
• Its willingness to respond to unmet medical needs contributes to ensuring the health of all (United Nations Sustainable Development Goal No
• Kurma Partners developed an ESG charter in 2020 and join on June 2021 the UN PRI
• Kurma Partners reconciles investor and market expectations in terms of transparency and strong commitment
• A policy of vigilance with strict inclusion or exclusion criteria has been implemented with regard to any subject relating to medical bioethics
• In 2020, Kurma Partners is committed to develop an Ethics Charter for its portfolio companies
• By promoting the best ESG practices, Kurma Partners collects extra-financial data on all its portfolio companies via a questionnaire
• Those information are consolidated in ESG section of each annual report

Download our ESG Charter Download our CSR Policy © COPYRIGHT KURMA PARTNERS LEGAL NOTICE       TERMS AND CONDITIONS       REGULATORY INFORMATION     PRIVATE POLICY     DESIGN : AGENCE K2